Long-term follow-up after induction treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in kidney allograft recipients: a double-blind, placebo-controlled trial.
van Gelder
T
T
Department of Internal Medicine, University Hospital Rotterdam, The Netherlands.
Zietse
R
R
Yzermans
J N
JN
Rischen-Vos
J
J
Vaessen
L M
LM
Weimar
W
W
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000961:Antilymphocyte Serum; D016572:Cyclosporine / Q000627:therapeutic use; D004311:Double-Blind Method; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000517:prevention & control*; D006085:Graft Survival / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D008775:Methylprednisolone / Q000627:therapeutic use; D010919:Placebos; D011241:Prednisone / Q000627:therapeutic use; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D015996:Survival Rate; D013997:Time Factors; D014184:Transplantation, Homologous
D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D010919:Placebos; D015375:Receptors, Interleukin-2; D016572:Cyclosporine; C079843:inolimomab; D011241:Prednisone; D008775:Methylprednisolone